An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD — PERSPECTIVES  

Macular Degeneration Clinical Trial

Official title: A 102-Week, Open Label, Multicenter Trial To Investigate The Efficacy Of Macugen For The Preservation Of Visual Function In Subjects With Neovascular Age-Related Macular Degeneration (AMD) And To Assess The Benefit Of Treating Early Choroidal Neovascularization (CNV).

Status Terminated

Clinical Trial Summary

The purpose of this study is to determine the benefits of treating subjects with neovascular age-related macular degeneration (AMD) at an earlier stage of choroidal neovascularization (CNV) as compared to those with established CNV. Additionally, the study would like to determine the efficacy of Macugen in preserving visual function in those subjects having CNV secondary to neovascular AMD.

Clinical Trial Description

A decision was made by the sponsor (08 May 2009) to terminate this study early; the study had achieved the primary objective prior to termination. This study was not terminated due to safety reasons. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Age Related Macular Degeneration (AMD)
• Choroidal Neovascularization
• Choroidal Neovascularization (CNV)
• Macular Degeneration
• Neovascularization, Pathologic
• Wet Macular Degeneration

• NCT number: NCT00327470
• Study type: Interventional
• Source: Pfizer
• Status: Terminated
• Phase: Phase 4
• Start date: July 2006
• Completion date: August 2009